购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

CHIR-99021

Rating icon 很棒
产品编号 T2310Cas号 252917-06-9
别名 Laduviglusib, CT99021, CHIR-99021

CHIR-99021 (CT99021) 是一种 Wnt/β-catenin 信号通路激活剂,也是一种 GSK-3α/β抑制剂 (IC50=10/6.7 nM),具有选择性和口服活性。CHIR-99021 可以诱导细胞自噬,可增强小鼠和人类胚胎干细胞的自我更新。

CHIR-99021

CHIR-99021

Rating icon 很棒
纯度: 99.29%
产品编号 T2310 别名 Laduviglusib, CT99021, CHIR-99021Cas号 252917-06-9

CHIR-99021 (CT99021) 是一种 Wnt/β-catenin 信号通路激活剂,也是一种 GSK-3α/β抑制剂 (IC50=10/6.7 nM),具有选择性和口服活性。CHIR-99021 可以诱导细胞自噬,可增强小鼠和人类胚胎干细胞的自我更新。

规格价格库存数量
1 mg
¥ 318
现货
2 mg
¥ 538
现货
5 mg
¥ 892
现货
10 mg
¥ 1,490
现货
25 mg
¥ 2,530
现货
50 mg
¥ 3,590
现货
100 mg
¥ 5,180
现货
200 mg
¥ 6,890
现货
500 mg
¥ 9,500
现货
1 mL x 10 mM (in DMSO)
¥ 933
现货
大包装 & 定制
加入购物车
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
实验操作小课堂
常见问题解答
查看更多

"CHIR-99021"的相关化合物库

选择批次:
纯度:≥95%
联系我们获取更多批次信息

产品介绍

生物活性
产品描述
CHIR-99021 (CT99021) is an activator of the Wnt/β-catenin signaling pathway and a GSK-3α/β inhibitor (IC50=10/6.7 nM) with selective and oral activity.CHIR-99021 induces cellular autophagy, which enhances self-renewal in mouse and human embryonic stem cells.
靶点活性
GSK-3α:10 nM (cell free), GSK-3β:6.7 nM (cell free)
体外活性
方法:小鼠干细胞 ES-D3 用 CHIR-99021 (1-10 µM) 处理 72 h,使用 MTT 方法检测细胞生长抑制情况。
结果:CHIR-99021 剂量依赖性地抑制 ES-D3 细胞生长,IC50 为 4.9 µM。[1]
方法:小鼠胚胎干细胞 J1 mESCs 和小鼠胚胎瘤细胞 F9 mEC 用 CHIR-99021 (3 μM) 处理 24 h,使用 immunofluorescence 方法检测靶点蛋白表达水平。
结果:CHIR-99021 处理后,J1-mESCs 和 F9-mEC 细胞的细胞质和细胞核中的β-连环蛋白增加。[2]
方法:人 Tenon 成纤维细胞 HTFs 用 CHIR-99021 (5 μM) 处理 48 h,使用 Western Blot 方法检测靶点蛋白表达水平。
结果:CHIR-99021 处理使活性形式的 GSK-3β (p-GSK-3β (Y216)) 的产生显著减少。[3]
体内活性
方法:为检测体内抗肿瘤活性,将 CHIR-99021 (37.5 mg/kg/第 0-3、6-10、13-17 和 20 天每天两次) 口服给药和 paclitaxel (10 mg/kg/第 0 天单次给药) 腹腔注射给携带人非小细胞肺癌肿瘤 H1975 的 Balb/c nude 小鼠。
结果:CHIR-99021 和 paclitaxel 在体内协同作用,抑制 NSCLC 肿瘤的生长。[4]
方法:为研究 GSK-3 的直接药理学抑制是否会改变酒精在小鼠体内的积极增强作用,将 CHIR-99021 (1-10 mg/kg) 单次腹腔注射给有酒精或蔗糖自给药史的 C57BL/6J 小鼠。
结果:CHIR-99021 剂量依赖性地增加了酒精强化反应,而对蔗糖自我给药或运动活性没有影响。CHIR-99021 显著降低了 pGSK-3β 在所有测试脑区的表达,仅在 NAcb 中降低了 PICK1 并增加了 GluA2 的总表达。[5]
激酶实验
Kinases were purified from SF9 cells through the use of their His or Glu tag. Glu-tagged proteins were purified as described, and His-tagged proteins were purified according to the manufacturer's instructions. Kinase assays were performed in 96-well plates with appropriate peptide substrates in a 300-μl reaction buffer (variations on 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 25 mMβ-glycerophosphate, 1 mM NaF, and 0.01% bovine serum albumin). Peptides had Km values from 1 to 100 μM. CHIR 99021 or CHIR GSKIA was added in 3.5 μl of Me2SO, followed by ATP to a final concentration of 1 μM. After incubation, triplicate 100-μl aliquots were transferred to Combiplate 8 plates containing 100 μl/well of 50 μM ATP and 20 mM EDTA. After 1 hour, the wells were rinsed five times with phosphate-buffered saline, filled with 200 μl of scintillation fluid, sealed, and counted in a scintillation counter 30 min later. All of the steps were at room temperature. The percentage of inhibition was calculated as 100 × (inhibitor ? no enzyme control)/(Me2SO control ? no enzyme control) [4].
细胞实验
The Wnt/beta-catenin reporter assay was performed with the M50 Super 8× TOPFlash and M51 Super 8× FOPFlash vector containing the firefly luciferase gene under the control of TCF/LEF binding sites or mutated bindings sites. 12,500 cells were seeded overnight on gelatine-coated 96-well plates in LIF-containing ES cell medium. On the next day, the cells were transfected using Lipofectamine with one of the aforementioned vectors plus pGL4.75 [hRluc/CMV] encoding the renilla luciferase reporter gene hRluc as a transfection control. Six hours after transfection the medium was changed to medium devoid of LIF, with reduced serum, and supplemented with 5 μM CHIR-99021. The Dual-Luciferase? reporter assay system was employed 48 and 72 h after the medium change to follow the luminescence reaction using a GloMax?-multi detection system [4].
动物实验
Blood was obtained by shallow tail snipping at lidocaine-anesthetized tips. Blood glucose was measured directly or heparinized plasma was collected for measurement of glucose or insulin. Animals were pre-bled and randomized to vehicle control or GSK-3 inhibitor treatment groups. For glucose tolerance tests (GTTs), animals fasted throughout the procedure with food removal early in the morning, 3 h before the first prebleed (db/db mice), or the previous night, 16 h before the bleed (ZDF rats). When the time course of plasma glucose and insulin changes in fasting ZDF rats was measured, food was removed ~16 h before test agent administration. The glucose challenges in the GTT were 1.35 g/kg i.p. (ipGTT) or 2 g/kg via oral gavage (oGTT). CHIR-99021 were formulated as solutions in 20 mmol/l citrate-buffered 15% Captisol or as fine suspensions in 0.5% carboxymethylcellulose [1].
别名Laduviglusib, CT99021, CHIR-99021
化学信息
分子量465.34
分子式C22H18Cl2N8
CAS No.252917-06-9
SmilesCc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl
密度1.48 g/cm3
储存&溶解度
存储store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 0.93 mg/mL (2 mM), In vivo: Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
DMSO: 50 mg/mL (107.45 mM), Sonication is recommended.
溶液配制表
DMSO
1mg5mg10mg50mg
5 mM0.4298 mL2.1490 mL4.2979 mL21.4897 mL
10 mM0.2149 mL1.0745 mL2.1490 mL10.7448 mL
20 mM0.1074 mL0.5372 mL1.0745 mL5.3724 mL
50 mM0.0430 mL0.2149 mL0.4298 mL2.1490 mL
100 mM0.0215 mL0.1074 mL0.2149 mL1.0745 mL

SCI 文献

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy CHIR-99021 | purchase CHIR-99021 | CHIR-99021 cost | order CHIR-99021 | CHIR-99021 chemical structure | CHIR-99021 in vivo | CHIR-99021 in vitro | CHIR-99021 formula | CHIR-99021 molecular weight